Glioblastoma multiforme formation and EMT: Role of FoxM1 transcription factor

Current Pharmaceutical Design

Volumn 21, Issue 10, 2015, Pages 1268-1271

  Wang, Zhongyong ^a,b   Zhang, Sicong ^a   Siu, Timothy L ^a   Huang, Suyun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Angiogenesis; EMT; FoxM1; Glioblastoma; Invasion; Tumorigenesis; Wnt catenin signaling

Indexed keywords

BETA CATENIN; FORKHEAD TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; TUMOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; FORKHEAD BOX PROTEIN M1; FOXM1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANGIOGENESIS; ARTICLE; ASTROCYTE; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR INVASION; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; BRAIN TUMOR; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN NEOPLASMS; CARCINOGENESIS; EPITHELIAL-MESENCHYMAL TRANSITION; FORKHEAD BOX PROTEIN M1; FORKHEAD TRANSCRIPTION FACTORS; GLIOBLASTOMA; HUMANS; TRANSCRIPTION FACTORS;

EID: 84926386329     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666141211115949     Document Type: Article

References (51)

1. Laoukili J, Kooistra MR, Bras A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005; 7: 126-36.
2. Wang IC, Chen YJ, Hughes D, et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 2005; 25: 10875-94.
3. Koo CY, Muir KW, Lam EW. FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta 2012; 1819: 28-37.
4. Kalin TV, Ustiyan V, Kalinichenko VV. Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models. Cell Cycle 2011: 10: 396-405.
5. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007; 7: 847-59.
6. Wang Z, Ahmad A, Li Y, et al. Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev 2010; 36: 151-6.
7. Priller M, Poschl J, Abrao L, et al. Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin Cancer Res 2011; 17: 6791-801.
8. Anders L, Ke N, Hydbring P, et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011; 20: 620-34.
9. Kong X, Li L, Li Z, et al. Dysregulated Expression of FOXM1 Isoforms Drives Progression of Pancreatic Cancer. Cancer Res 2013; 73: 3987-96.
10. Li D, Wei P, Peng Z, et al. The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis. Clin Cancer Res 2013; 19: 62-72.
11. Liu M, Dai B, Kang SH, et al. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 2006; 66: 3593-602.
12. Zhang N, Wei P, Gong A, et al. FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011; 20: 427-42.
13. Zhang Y, Zhang N, Dai B, et al. FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res 2008: 68: 8733-42.
14. Zheng H, Ying H, Wiedemeyer R, et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell 2010; 17: 497-509.
15. Dai B, Kang SH, Gong W, et al. Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene 2007; 26: 6212-9.
16. Dai B, Pieper RO, Li D, et al. FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes. Cancer Res 2010; 70: 2951-61.
17. Radhakrishnan SK, Bhat UG, Hughes DE, et al. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res 2006; 66: 9731-5.
18. Hegde NS, Sanders DA, Rodriguez R, Balasubramanian S. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem 2011; 3: 725-31.
19. Li Y, Zhang S, Huang S. FoxM1: a potential drug target for glioma. Future Oncol 2012; 8: 223-6.
20. Cen L, Carlson BL, Pokorny JL, et al. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. Neuro Oncol 2013; 15: 735-46.
21. Surawicz TS, Davis F, Freels S, et al. H.R. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 1998; 40: 151-60.
22. Hodgson JG, Yeh RF, Ray A, et al. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol 2009; 11: 477-87.
23. Giese A, Bjerkvig R, Berens ME, et al. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21: 1624-36.
24. Hu B, Jarzynka MJ, Guo P, et al. Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway. Cancer Res 2006; 66: 775-83.
25. Bao B, Wang Z, Ali S, et al. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cellular Biochem 2011; 112(9): 2296-306.
26. Huang C, Xie D, Cui J, Li Q, Gao Y, Xie K. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system. Clinical cancer research : an official journal of the American Association for Cancer Res 2014 15; 20(6): 1477-88.
27. Yang C, Chen H, Tan G, et al. FOXM1 promotes the epithelial to mesenchymal transition by stimulating the transcription of Slug in human breast cancer. Cancer Letters 2013 28; 340(1): 104-12.
28. Wang Y, Yao B, Wang Y, et al. Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer. Int J Mol Med 2014; 33(6): 1514-22.
29. Miao L, Xiong X, Lin Y, et al. Down-regulation of FoxM1 leads to the inhibition of the epithelial-mesenchymal transition in gastric cancer cells. Cancer Genetics 2014; 207(3): 75-82.
30. Kong FF, Qu ZQ, Yuan HH, et al. Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in nonsmall cell lung cancer. Oncol Reports 2014; 31(6): 2660-8.
31. Pan SJ, Zhan SK, Pei BG, Sun QF, Bian LG, Sun BM. MicroRNA-149 inhibits proliferation and invasion of glioma cells via blockade of AKT1 signaling. Int J Immunopathol Pharmacol 2012; 25(4): 871-81.
32. Ke Y, Zhao W, Xiong J, Cao R. miR-149 Inhibits Non-Small-Cell Lung Cancer Cells EMT by Targeting FOXM1. Biochem Res Int 2013; 2013: 506731.
33. Zhang Y, Kim J, Mueller AC, et al. Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma. Cell Death Differentiation 2014; 21(5): 720-34.
34. Li J, Wang Y, Luo J, et al. miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS letters 2012 19; 586(20): 3761-5.
35. Mahabir R, Tanino M, Elmansuri A, et al. Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma. Neuro Oncol 2014; 16(5): 671-85.
36. Xue J, Lin X, Chiu W, et al. Sustained activation of SMAD3/4 by FOXM1 promotes TGF-β-dependent cancer metastasis. J Clin Investigation 2014; 124(2): 564-79.
37. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
38. Feldkamp MM, Lau N, Rak J, et al. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int J Cancer 1999; 81: 118-24.
39. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001; 15: 1311-33.
40. Bachoo RM, Maher EA, Ligon KL, et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002; 1: 269-77.
41. Network, TC. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-8.
42. Zheng H, Ying H, Yan H, Kimmelman AC, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008; 455: 1129-33.
43. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-80.
44. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149: 1192-205.
45. Huang H, He X. Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol 2008; 20: 119-25.
46. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26.
47. Jin X, Jeon HY, Joo KM, et al. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res 2011; 71: 3066-75.
48. Pu P, Zhang Z, Kang C, et al. Downregulation of Wnt2 and betacatenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther 2009; 16: 351-61.
49. Pulvirenti T, Van Der Heijden M, Droms LA, et al. Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas. Cancer Res 2011; 71: 7280-90.
50. Rossi M, Magnoni L, Miracco C, et al. beta-catenin and Gli1 are prognostic markers in glioblastoma. Cancer Biol Ther 2011; 11: 753-61.
51. Mirza MK, Sun Y, Zhao YD, et al. FoxM1 regulates re-annealing of endothelial adherens junctions through transcriptional control of beta-catenin expression. J Exp Med 2010; 207: 1675-85.